Propylene Oxide Addition Effect on the Chemical Speciation of a Fuel-Rich Premixed -Heptane/Toluene Flame.

1,2-Propylene oxide (PO, CHO) is considered as a promising agent for improving fuel. In this work, the effect of PO additives on the species pool in a premixed burner-stabilized fuel-rich (ϕ = 1.6) flame fueled by -heptane/toluene mixture (7/3 by volume of liquids) at atmospheric pressure is studied by the flame-sampling molecular beam mass spectrometry and numerical modeling in order to get insight into the chemical aspects of the influence of oxygenates with an epoxy group on the formation of abundant intermediates (including PAH precursors) during combustion of fossil fuels.

Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of and for the Dominant Disease.

Heterotrimeric G proteins are immediate transducers of G protein-coupled receptors-the biggest receptor family in metazoans-and play innumerate functions in health and disease. A set of de novo point mutations in and , the genes encoding the α-subunits (Gαo and Gαi1, respectively) of the heterotrimeric G proteins, have been described to cause pediatric encephalopathies represented by epileptic seizures, movement disorders, developmental delay, intellectual disability, and signs of neurodegeneration. Among such mutations, the Gln52Pro substitutions have been previously identified in and .

[Experience of using ketogenic diet in a patient with glucose transporter 1 deficiency syndrome (a case report)].

Unlabelled: We present the experience of using the ketogenic diet (KD) in the treatment of pharmacoresistant epilepsy in a patient with glucose transporter deficiency syndrome type I (GLUT1). We observed a nine-year-old boy with refractory epilepsy with frequent multiple myoclonic seizures due to GLUT1. The high effectiveness of KD in the treatment of GLUT1 was demonstrated.

[Use of ketogenic diet in treatment of pharmacoresistant epilepsy].

Ketogenic diet (KD) is one of the most effective methods of epilepsy non-drug therapy. Ten patients with pharmacoresistant epilepsy, aged 1.5-18 years, were treated with individually matched and strictly controlled KD with high fat content and restricted amount of proteins and carbohydrates.